The Investment Whisperer
  • Business
  • Politics
  • Investing
  • World
  • Business
  • Politics
  • Investing
  • World

The Investment Whisperer

Investing

RAD 202 receives approval to start Phase 1 therapeutic trial

by admin December 20, 2024
December 20, 2024
RAD 202 receives approval to start Phase 1 therapeutic trial

Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial

Download the PDF here.

This post appeared first on investingnews.com

0
FacebookTwitterGoogle +Pinterest
previous post
Westgold Shares Scoping Study for Expansion of Fortnum Gold Operation
next post
Forum Comments on Share Price

Related Posts

Stardust Power Acquires Site, Receives Key Permit And...

December 22, 2024

Completion of Institutional Component of Entitlement Offer and...

May 27, 2024

Element79 Provides Corporate Updates

January 31, 2025

Amended Announcement – Piedra Redonda Gas Project Assessment

October 17, 2024

Grid Battery Metals Team Provides Nevada Exploration Update...

February 8, 2024

Completion of US$5M MIIF Subscription

January 27, 2024

Uranium Price Update: Q3 2024 in Review

October 29, 2024

Murchison South Increases to 67koz Gold Across Two...

May 13, 2025

Top 5 Canadian Uranium Stocks of 2024

February 24, 2024

Crypto Market Recap: Senator Cruz Supports Bitcoin Mining...

April 3, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (1,550)
    • Investing (4,198)
    • Politics (5,576)
    • World (4,762)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: TheInvestmentWhisperer.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 TheInvestmentWhisperer.com | All Rights Reserved